Switch theme
Sign up to access all valuation multiples
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
2023
299
Last FY Revenue $212M
Last FY EBITDA $72.1M
$438M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Zhengye Biotechnology achieved revenue of $212M and an EBITDA of $72.1M.
Zhengye Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhengye Biotechnology valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $212M | XXX | XXX | XXX |
| Gross Profit | XXX | $130M | XXX | XXX | XXX |
| Gross Margin | XXX | 61% | XXX | XXX | XXX |
| EBITDA | XXX | $72.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 34% | XXX | XXX | XXX |
| EBIT | XXX | $57.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | 27% | XXX | XXX | XXX |
| Net Profit | XXX | $31.5M | XXX | XXX | XXX |
| Net Margin | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | $74.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zhengye Biotechnology's stock price is $9.
Zhengye Biotechnology has current market cap of $427M, and EV of $438M.
See Zhengye Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $438M | $427M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zhengye Biotechnology has market cap of $427M and EV of $438M.
Zhengye Biotechnology's trades at 2.1x EV/Revenue multiple, and 6.1x EV/EBITDA.
Equity research analysts estimate Zhengye Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhengye Biotechnology's P/E ratio is not available.
See valuation multiples for Zhengye Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $427M | XXX | $427M | XXX | XXX | XXX |
| EV (current) | $438M | XXX | $438M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 7.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 13.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZhengye Biotechnology's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Zhengye Biotechnology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zhengye Biotechnology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zhengye Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhengye Biotechnology acquired XXX companies to date.
Last acquisition by Zhengye Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhengye Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zhengye Biotechnology founded? | Zhengye Biotechnology was founded in 2023. |
| Where is Zhengye Biotechnology headquartered? | Zhengye Biotechnology is headquartered in United States of America. |
| How many employees does Zhengye Biotechnology have? | As of today, Zhengye Biotechnology has 299 employees. |
| Who is the CEO of Zhengye Biotechnology? | Zhengye Biotechnology's CEO is Mr. Songlin Song. |
| Is Zhengye Biotechnology publicy listed? | Yes, Zhengye Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Zhengye Biotechnology? | Zhengye Biotechnology trades under ZYBT ticker. |
| When did Zhengye Biotechnology go public? | Zhengye Biotechnology went public in 2025. |
| Who are competitors of Zhengye Biotechnology? | Similar companies to Zhengye Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zhengye Biotechnology? | Zhengye Biotechnology's current market cap is $427M |
| Is Zhengye Biotechnology profitable? | Yes, Zhengye Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
